Doctors Without Borders Urges Pharmaceutical Corporations to Release Clinical Data to Help Develop Urgently Needed New TB Regimens | MSF USA

lterrat's bookmarks 2017-03-26

Summary:

"oday, World Tuberculosis Day, Doctors Without Borders/Médecins Sans Frontières’ (MSF) is urging pharmaceutical corporations, Sequella and Pfizer, to provide open access to all existing clinical data on a promising drug, sutezolid, to help accelerate the research and development of urgently needed new, lifesaving TB treatment regimes. This data, if not released, will take years and resources to replicate, further delaying new treatment options for people living with TB.

Johns Hopkins University (JHU), which holds several patents for the drug sutezolid, recently agreed to a deal with the Medicines Patent Pool (MPP) to allow multiple drug developers—including product development organizations, companies and governments—to conduct research and develop TB treatment combinations that include sutezolid. The MPP is an organization funded by UNITAID that works to increase innovation and access to drugs through voluntary patent licensing.

Pfizer held rights on sutezolid and signed an exclusive license with Sequella in 2013. However, research has stalled and no new studies of sutezolid have been successfully conducted. The primary patent on sutezolid expired in 2014, but Pfizer, Sequella and JHU still hold secondary patents and clinical data on the drug. MSF is part of a coalition of public health groups that recently sent this letter to Sequella."

Link:

http://www.doctorswithoutborders.org/article/doctors-without-borders-urges-pharmaceutical-corporations-release-clinical-data-help-develop

From feeds:

Open Access Tracking Project (OATP) » lterrat's bookmarks

Tags:

oa.pharma

Date tagged:

03/26/2017, 00:33

Date published:

03/25/2017, 20:33